Clinical Trial Update: A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

This is a Phase 3 bioequivalence study updating on comparing generic mesalamine 400 mg to ASACOL 400 mg in patients with mild-to-moderate ulcerative colitis; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ASACOL 400 mg (mesalamine)
• Mesalamine 400 mg (mesalamine)

Snippet

Sponsor: EMET Pharmaceuticals, LLC | Conditions: Mild to Moderate Ulcerative Colitis | Phase 3 | Status: COMPLETED